# Protagonist Therapeutics, Inc: overview

PTGX · Nasdaq · CIK 1377121 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ptgx.md) · [Financials](/companies/ptgx/financials.md) · [Filings](/companies/ptgx/filings.md) · [Insiders](/companies/ptgx/insiders.md)

Latest reported revenue: [$213.5m](/filings/0001104659-26-091123.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-091123).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.7](/filings/0001104659-25-107816.md) | [171 d](/filings/0001104659-26-019696.md) | [28.3](/filings/0001104659-26-055661.md) | [5.5](/filings/0001104659-26-091123.md) | [4.7](/filings/0001104659-25-107816.md) | [7.4 d](/filings/0001104659-26-019696.md) | [56.4](/filings/0001104659-26-055661.md) | [213](/filings/0001104659-26-091123.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(886.7%)](/filings/0001104659-25-107816.md) | [74.3% d](/filings/0001104659-26-019696.md) | [(68.2%)](/filings/0001104659-26-055661.md) | [(758.0%)](/filings/0001104659-26-091123.md) | [(985.2%)](/filings/0001104659-25-107816.md) | [(677.1%) d](/filings/0001104659-26-019696.md) | [(6.5%)](/filings/0001104659-26-055661.md) | [74.4%](/filings/0001104659-26-091123.md) |
| Net margin | % | [(710.4%)](/filings/0001104659-25-107816.md) | [77.2% d](/filings/0001104659-26-019696.md) | [(41.2%)](/filings/0001104659-26-055661.md) | [(627.0%)](/filings/0001104659-26-091123.md) | [(834.9%)](/filings/0001104659-25-107816.md) | [(596.8%) d](/filings/0001104659-26-019696.md) | [6.7%](/filings/0001104659-26-055661.md) | [76.3%](/filings/0001104659-26-091123.md) |
| Diluted EPS | $ per share | [(0.54)](/filings/0001104659-25-107816.md) | not reported | [(0.19)](/filings/0001104659-26-055661.md) | [(0.55)](/filings/0001104659-26-091123.md) | [(0.62)](/filings/0001104659-25-107816.md) | not reported | [0.05](/filings/0001104659-26-055661.md) | [2.29](/filings/0001104659-26-091123.md) |
| Free cash flow | $m | [(28.6) d](/filings/0001104659-25-107816.md) | [(29.5) d](/filings/0001104659-26-019696.md) | [125](/filings/0001104659-26-055661.md) | [(29.6) d](/filings/0001104659-26-091123.md) | [(2.0) d](/filings/0001104659-25-107816.md) | [(37.1) d](/filings/0001104659-26-019696.md) | [(49.2)](/filings/0001104659-26-055661.md) | [219 d](/filings/0001104659-26-091123.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [27.4](/filings/0001558370-24-001850.md) | [26.6](/filings/0001558370-25-001317.md) | [60.0](/filings/0001104659-26-019696.md) | [434](/filings/0001104659-26-019696.md) | [46.0](/filings/0001104659-26-019696.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(460.0%)](/filings/0001558370-24-001850.md) | [(494.2%)](/filings/0001558370-25-001317.md) | [(156.1%)](/filings/0001104659-26-019696.md) | [58.2%](/filings/0001104659-26-019696.md) | [(343.6%)](/filings/0001104659-26-019696.md) |
| Net margin | % | [(458.9%)](/filings/0001558370-24-001850.md) | [(479.3%)](/filings/0001558370-25-001317.md) | [(131.6%)](/filings/0001104659-26-019696.md) | [63.3%](/filings/0001104659-26-019696.md) | [(282.8%)](/filings/0001104659-26-019696.md) |
| Diluted EPS | $ per share | [(2.71)](/filings/0001558370-24-001850.md) | [(2.60)](/filings/0001558370-25-001317.md) | [(1.39)](/filings/0001104659-26-019696.md) | [4.23](/filings/0001104659-26-019696.md) | [(2.05)](/filings/0001104659-26-019696.md) |
| Free cash flow | $m | [(109)](/filings/0001558370-24-001850.md) | [(109)](/filings/0001558370-25-001317.md) | [(70.8)](/filings/0001104659-26-019696.md) | [183](/filings/0001104659-26-019696.md) | [56.1](/filings/0001104659-26-019696.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ptgx/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2016-08-16 | [Johnson & Johnson](/insiders/200406.md) | 10% owner | Purchase (P) | 583,333 | $12.00 | $7.0m | [Form 4](/filings/0000904454-16-001373.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.26bn | 10,307,837 |  | Added +528,468 |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $778.2m | 6,348,906 |  | Unchanged |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $620.4m | 5,061,175 |  | Added +2,122 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $444.9m | 3,629,298 |  | Added +148,087 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $418.8m | 3,416,781 |  | Reduced −182,863 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $416.7m | 3,399,221 |  | Reduced −1,778,575 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $407.2m | 3,321,554 |  | Added +204,805 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $349.8m | 2,853,394 |  | Added +47,498 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $304.9m | 2,891,527 |  | Not compared |
| [JOHNSON & JOHNSON](/funds/200406.md) | 2026-06-30 | $300.2m | 2,449,183 |  | Unchanged |

## Recent filings

[All 687 filings](/companies/ptgx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:17 ET | [10-Q](/filings/0001104659-26-091123.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091123 |
| 2026-08-05 | 16:11 ET | [8-K](/filings/0001104659-26-091099.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-091099 |
| 2026-06-18 | 16:30 ET | [8-K](/filings/0001104659-26-075777.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-075777 |
| 2026-05-05 | 16:27 ET | [10-Q](/filings/0001104659-26-055661.md) | Quarterly report, period 2026-03-31 | 0001104659-26-055661 |
| 2026-05-05 | 16:08 ET | [8-K](/filings/0001104659-26-055629.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-055629 |
| 2026-04-28 | 16:44 ET | [DEF 14A](/filings/0001104659-26-050429.md) | Proxy statement, period 2026-06-17 | 0001104659-26-050429 |
| 2026-02-25 | 16:28 ET | [10-K](/filings/0001104659-26-019696.md) | Annual report, period 2025-12-31 | 0001104659-26-019696 |
| 2026-02-25 | 16:08 ET | [8-K](/filings/0001104659-26-019658.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-019658 |
| 2026-01-12 | 08:00 ET | [8-K](/filings/0001104659-26-002724.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-002724 |
| 2025-11-06 | 16:52 ET | [10-Q](/filings/0001104659-25-107816.md) | Quarterly report, period 2025-09-30 | 0001104659-25-107816 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-019696.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e6d63365-8e7d-48bc-81bd-0bb608816288)

## About the filer

- CIK: 1377121
- Tickers: PTGX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:29 ET. No prices; not investment advice.